Ambrx Biopharma Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $9.95 |
| Prev. Close | $10.02 |
| EPS | 0.42 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 9, 2023 |
| Dividend Yield % | - |
| Market Cap | $732.98M |
| PE Ratio | 27.90 |
| low | high | |
|---|---|---|
| Day Range | 9.95 | 11.81 |
| 52 Week Range | 0.38 | 16.86 |
| Ratios | |
|---|---|
| P/B Ratio | 2.51 |
| Revenue | $3.44M |
| Operating M. % | -48,350.94% |
| Earnings | -$67.05M |
| Earnings Growth % | - |
| EBITDA Margin % | -1,792.34% |
| ROE % | -37.23% |
| EPS | 0.42 |
Score Breakdown
All Score (66 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| AMAM | Market | |
|---|---|---|
| Value | 52 | 42 |
| Quality | 45 | 46 |
| Ownership | 68 | 39 |
| Growth | 80 | 44 |
| Dividends | - | 32 |
All Score (66 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Ambrx Biopharma Inc. (AMAM)
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. It is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, the company is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Daniel J. O'Connor J.D.
- Headquarters
- La Jolla
- Employees
- 79
Keep an eye on Ambrx Biopharma Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.